1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsThis omnibus solicitation offers STTR grant funding for small businesses to obtain non-dilutive funding for early-stage research and development, requiring a formal collaboration with a research institution.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Small businesses in partnership with a non-profit research institution. Specific eligibility requirements are detailed in the full announcement. Confirm the full requirements in the official notice before applying.
PHS 2023 Omnibus Solicitation of the NIH and CDC for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed) is funded by National Institutes of Health (NIH) and Centers for Disease Control and Prevention (CDC). Verify program details on the funder's official page before applying.
Past winners and funding trends for this program
Small Business Transition Grant for New Entrepreneurs (R43/R44 Clinical Trial Not Allowed) is sponsored by National Institutes of Health (NIH) and Centers for Disease Control and Prevention (CDC). This program supports small businesses developing promising technologies and products that align with the NIH and CDC missions to improve health and save lives. It specifically aims to help early-career scientists and professionals with limited entrepreneurial experience transition into entrepreneurial roles.
PHS 2023 Omnibus Solicitation of the NIH and CDC for Small Business Innovation Research Grant Applications is sponsored by National Institutes of Health (NIH) and Centers for Disease Control and Prevention (CDC). This omnibus solicitation invites small businesses to submit innovative research proposals in health and behavioral training technologies. Applications are accepted three times a year, with the next deadline on January 5, 2027.
PHS 2024-2 Omnibus Solicitation of the NIH and CDC for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed) is sponsored by National Institutes of Health (NIH) and Centers for Disease Control and Prevention (CDC). This omnibus solicitation supports investigator-initiated Small Business Innovation Research (SBIR) grant applications for projects that do not involve clinical trials. It encourages small businesses to propose innovative solutions across a broad range of topics relevant to the missions of NIH and CDC.
PHS 2023 Omnibus Solicitation of the NIH and CDC for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed) is sponsored by National Institutes of Health (NIH). This program supports small businesses in developing innovative technologies that align with the NIH's mission to improve health. This includes research and development in mental health technologies, digital health, and AI applications. The program encourages proposals that have the potential for commercial success or significant societal benefits.
Notice of Special Interest (NOSI): RNA Delivery Technologies to Allow Specific Tissue Target Homing (RNA-DASH) is sponsored by National Institute of Allergy and Infectious Diseases (NIAID) / NIH. NIAID invites small business grant applications proposing to test and evaluate non-viral technologies capable of delivering RNA-based therapeutics into disease-relevant cells and tissues in vivo. This includes specific sites of infection, such as the lung, relevant for the treatment of HIV-associated co-infections like tuberculosis. This NOSI leverages parent small business funding opportunities.
PHS 2023 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Optional) is sponsored by National Institutes of Health (NIH). This solicitation supports cooperative research and development between small businesses and non-profit research institutions (e. g. , universities or federally funded research centers) for Small Business Technology Transfer (STTR) grant applications.
Bloomberg Philanthropies committed $150 million on October 20, 2026 to its Overdose Prevention Initiative, adding Washington state, continuing in Kentucky, New Jersey, New Mexico, North Carolina and Wisconsin, and exiting the two original 2018 states. The money flows through state partnerships, not an open call. Here is how organizations in those states can actually engage.
Read articlePAR-27-003 opens the NIGMS-style RM1 to 13 NIH institutes through September 2029: 3 to 6 PIs, up to $1.5M in direct costs a year but most awards $500K to $900K, at least 2.4 months of effort per PI, and a 20-page strategy with a mandatory Team Integration Plan. The NIGMS predecessor made 4 new awards in three years.
Read articleThe October 6, 2026 Director's Awards cohort is NIH's most expensive in four years at about $4.1 million per award. New Innovator rebounded from 29 to 42 while Early Independence fell from 13 to 3 after the program skipped its FY2026 competition. Here is what the composition shift means for FY2027 and FY2028 applicants.
Read article